Either early signs are surfacing that GLP-1 trends are beginning to stall, or these products are simply going through the normal course of business with peak potential intact
J., Berryman, D
After propensity-score matching, the two cohorts (1051 in each cohort, mean age 52.6 years, 41.5% women, 16.6% black, 66.2% white, 7.4% Hispanic) were balanced (Table 2)
Food intake and body weight were measured twice weekly
Rather, it may provide complementary cardiovascular benefits in appropriate patient populations, particularly those with obesity or type 2 diabetes who have not achieved adequate lipid control with lifestyle modifications and standard pharmacotherapy alone
To keep it short and simple: retatrutide is still undergoing clinical trials, so it's not approved yet in the UK [6]